Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
1. Patients not currently receiving metformin:
For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
2. Patients receiving metformin:
For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. The combination of sitagliptin and metformin works together to effectively lower blood sugar levels. Therefore, it plays an important role in facilitating blood sugar management and improving diabetes symptoms.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
1. Patients not currently receiving metformin:
For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
2. Patients receiving metformin:
For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This medication consists of two components, each helping to control blood sugar.
First, the sitagliptin component can cause rare but serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips occur within 3 months of administration, discontinue the medication immediately and consult a doctor.
Additionally, sitagliptin may cause pancreatitis, which is inflammation of the pancreas, so if there is abdominal pain, vomiting, or persistent abdominal discomfort, inform medical personnel immediately.
The metformin component can cause lactic acidosis, a rare but life-threatening metabolic disturbance; thus, this medication should not be taken by individuals with impaired kidney function, dehydration, severe infections, or heart conditions.
Especially in patients with moderate to severe renal impairment, acute heart failure, or acute myocardial infarction, this medication should not be used.
If iodine contrast agents are to be administered for radiological examinations, this medication must be discontinued before and after the examination, and should only be resumed after confirming normal kidney function.
It is advisable for pregnant or breastfeeding women to avoid this medication, as its safety and effectiveness in children under 18 years of age have not been established.
While taking this medication, regular kidney function and blood tests should be conducted, and it is recommended to periodically check vitamin B12 levels.
Alcohol may increase the risk of side effects from this medication, so excessive drinking should be avoided during treatment.
Furthermore, if used together with other diabetes medications or insulin, hypoglycemic symptoms may occur, so blood sugar should be closely monitored, and medication dosage adjusted in consultation with a physician, if necessary.
If undergoing surgery, the medication should be stopped 48 hours before the procedure and can be resumed only after oral intake is possible and kidney function is confirmed as normal.
Finally, if unusual skin rashes, severe joint pain, or blistering skin conditions occur while taking this medication, inform a doctor immediately, and discontinue the medication if such symptoms arise.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory tract infection
headache
nausea
Show 24 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
vesiculobullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
vitamin B12 deficiency
dermatitis
anorexia
weight loss
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
gastrointestinal disorders
itching
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly closed container that is well ventilated, at a temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication over time.
Appearance and packaging
Appearance
Pink oval film-coated tablet
Package unit
30 tablets/bottle, 120 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.